Symptomtext
medical assistant should give FLUZONE HIGH-DOSE QIV and a COVID-19 vaccine. but their MA accidentally ended up giving FLUZONE HIGH-DOSE QIV and FLUZONE QIV NP to the patient with no reported adverse event; medical assistant should give FLUZONE HIGH-DOSE QIV and a COVID-19 vaccine. but their MA accidentally ended up giving FLUZONE HIGH-DOSE QIV and FLUZONE QIV NP to the patient with no reported adverse event; Initial information was received on 29-Nov-2023 regarding an unsolicited valid non-serious case received from a other health professional. This case involves 81 years old female patient who experienced medical assistant should give influenza quadrival a-b high dose hv vaccine [Fluzone HIGH-DOSE QUADRIVALENT] and a covid-19 vaccine. but their ma accidentally ended up giving influenza quadrival a-b high dose hv vaccine [Fluzone HIGH-DOSE QUADRIVALENT] and influenza quadrival a-b vaccine [Fluzone QUADRIVALENT] to the patient with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included pneumococcal vaccine CONJ 20V (CRM197) (Prevnar 20) for Immunisation. On 29-Nov-2023, the patient received a dose of 0.7 ml of suspect influenza quadrival a-b high dose hv vaccine lot UT8131BA, strength, formulation, expiry date was unknown via intramuscular route in the right and left deltoid, received a dose of 0.5 ml of suspect influenza quadrival a-b vaccine Suspension for injection ot UT8109KA, strength, expiry date was unknown via intramuscular route in unknown administration site, received a dose of suspect COVID-19 VACCINE not produced by Sanofi Pasteur lot number not reported via unknown route in unknown administration site for all prophylactic vaccination and medical assistant should give fluzone high-dose qiv and a covid-19 vaccine. but their ma accidentally ended up giving fluzone high-dose qiv and fluzone qiv np to the patient with no reported adverse event (wrong product administered) and (extra dose administered) (latency : same day). Action taken was not applicable. At time of reporting, the outcome was Unknown for the events. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.